Chemistry
B.S.
Jackson State University
1996
See all Profiles
Faculty
Faculty
Ranti Akiyode
Dean
Department/Office
- Dean's Office
School/College
- College of Pharmacy
Biography
Dr. Akiyode is a Professor of Pharmacy Practice and Dean at Howard University College of Pharmacy. She has over 20 years of experience as faculty member, including 16 years of clinical pharmacy practice. She is board certified in pharmacotherapy specialty, and is a diabetes care and education specialist. She is the founding pharmacist at the Howard University Hospital Diabetes Treatment Center where she established the delivery of medication therapy and diabetes management service in collaboration with endocrinologists, nurses, and dietician from 2007-2017. She received her doctorate degree in clinical pharmacy from the University of Mississippi School of Pharmacy in 2000. She completed a community pharmacy residency program at Leesburg Pharmacy. Dr. Akiyode is very passion about lifelong learning, leadership, and professional development for students, staff, and faculty. She received the Professionalism Recognition Award for Clinical Faculty in 2016, Faculty Preceptor of the Year Award in 2017, and the HU Pharmacy Alumni Association Distinguished Faculty of the Year Award in 2018. She has been a mentor to junior faculty, and coordinates the junior faculty mentoring program for the College of Pharmacy. In 2021, she completed the coveted one-year American Association of Colleges of Pharmacy Academic Leadership Fellows Program designed to develop the nation's most promising individuals at Colleges of Pharmacy to become future leaders in pharmacy and higher education.
Education & Expertise
Education
Pharmacy
Pharm.D.
University of Mississippi
2000
Expertise
Diabetes
I am a certified diabetes educator and available to provide updates on the new developments in the area of diabetes medications/prevention/prevalence.
Pharmacotherapy
Faculty development
Academics
Academics
Integrated Therapeutics: is an integration of pathophysiology and pharmacotherapy
This 5 weeks module focuses on Endocrine, Gastrointestinal, Renal, and Nutrition topics.
Research
Research
Specialty
Professionalism, Professional Development, DiabetesAccomplishments
Accomplishments
Distinguished Young Pharmacist Award (2002)
Innovative Pharmacy Practice Award (2003)
DC CB of American Association of Diabetes Educators “Diabetes Educator of the Year” (2011)
AACP Academic Leadership Fellows Program (2020-2021)
HU Pharmacy Alumni Association, Distinguished Faculty of the Year Award (2018)
Faculty Preceptor of the Year Award (2017)
Professionalism Recognition Award for Clinical Faculty (2016)
Nominated for Faculty Preceptor of the Year Award (2012, 2015, 2016)
HU-TEACH Program III Finalist (2015)
AACP Walmart Scholar Program Recipient: Faculty Mentor (2014, 2017)
Certified Diabetes Educator, CDE (2012)
Publications and Presentations
Publications and Presentations
Metformin has beneficial effects beyond diabetes management.http://www.aademeeting.org/metformin-has-beneficial-effects-beyond-diabe...
Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient
https://pmc.ncbi.nlm.nih.gov/articles/PMC4058735/
Type 2 diabetes mellitus is a metabolic disorder of deranged fat, protein and carbohydrate metabolism resulting in hyperglycemia as a result of insulin resistance and inadequate insulin secretion. Although a wide variety of diabetes therapies is available, yet limited efficacy, adverse effects, cost, contraindications, renal dosage adjustments, inflexible dosing schedules and weight gain significantly limit their use.
Ranibizumab: A Review of Its Use in the Treatment of Diabetic Retinopathy in Patients With Diabetic Macular Edema
To evaluate the pharmacotherapy role of ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor, for the treatment of diabetic retinopathy (DR) in patients with diabetic macular edema (DME).
Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications
Diabetes has been increasing in prevalence over the years, and nearly 30 million Americans (9.3%) now have diabetes. This disease burden on the population also translates to increased prevalence rates of diabetes complications. Diabetes is associated with several eye complications, including cataracts and glaucoma. However, the most common eye disorder associated with diabetes is diabetic retinopathy (DR), which is the leading cause of blindness among U.S. adults. During the 2005–2008 time period, >4 million adults ≥40 years of age with diabetes had retinopathy, including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR), which can lead to vision loss.